Stock Ratios
Making an investment decision in the stock market involves a certain amount of risk, so it's important to thoroughly review a company's stock before making any decisions. Stock float, number of short positions and outstanding shares are among the many factors an investor should take into account.
profit margin TTM
-0.01%
operating margin TTM
-31.26%
revenue TTM
622.21 Million
revenue per share TTM
11.12$
valuation ratios | |
|---|---|
| pe ratio | -152.29 |
| peg ratio | 1.19 |
| price to book ratio | 0.00 |
| price to sales ratio | 0.01 |
| enterprise value multiple | 2,853.33 |
| price fair value | 0.00 |
profitability ratios | |
|---|---|
| gross profit margin | 90.11% |
| operating profit margin | -31.26% |
| pretax profit margin | -30.07% |
| net profit margin | -0.01% |
| return on assets | -0.0% |
| return on equity | -0.01% |
| return on capital employed | -5.53% |
liquidity ratios | |
|---|---|
| current ratio | 1.80 |
| quick ratio | 1.56 |
| cash ratio | 0.46 |
efficiency ratios | |
|---|---|
| days of inventory outstanding | 1,521.69 |
| operating cycle | 1,522.02 |
| days of payables outstanding | 2.08 |
| cash conversion cycle | 1,519.93 |
| receivables turnover | 1,124.60 |
| payables turnover | 175.35 |
| inventory turnover | 0.24 |
debt and solvency ratios | |
|---|---|
| debt ratio | 0.02 |
| debt equity ratio | 0.03 |
| long term debt to capitalization | 0.03 |
| total debt to capitalization | 0.03 |
| interest coverage | 0.00 |
| cash flow to debt ratio | 0.01 |
cash flow ratios | |
|---|---|
| free cash flow per share | 3.29 |
| cash per share | 4,971.64 |
| operating cash flow per share | 3.31 |
| free cash flow operating cash flow ratio | 0.99 |
| cash flow coverage ratios | 0.01 |
| short term coverage ratios | 0.00 |
| capital expenditure coverage ratio | 156.54 |
Frequently Asked Questions
When was the last time Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN) reported earnings?
Supernus Pharmaceuticals, Inc. (SUPN) published its most recent earnings results on 06-11-2025.
What is Supernus Pharmaceuticals, Inc.'s current ROE?
An investor's main concern is the profitability ratios of a company so that they are able to understand how it performs financially. Investors are interested in finding out how effectively a business is using their cash to produce earnings, which is why return on equity (ROE) ratio is important. Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN)'s trailing twelve months ROE is -0.01%.
What are ROA telling us?
The Return on Assets (ROA) ratio measures how profitable a company is relative to its total assets. Supernus Pharmaceuticals, Inc. (SUPN) currently has a ROA of -0.0%. Companies that manage their assets effectively will have greater returns, while those that do so poorly would suffer lower returns.
Where did SUPN's net profit margin stand at?
SUPN reported a profit margin of -0.01% in the last quarter. A company's profit margin, also known as its revenue ratio or gross profit ratio, reflects the amount of revenue that an organization earns compared to its net income. In general, a higher ratio implies greater profit, and vice versa.
What is SUPN's short-term liquidity position?
Apple's current ratio, which measures its ability to pay short-term obligations, was 1.80 in the most recent quarter. The quick ratio stood at 1.56, with a Debt/Eq ratio of 0.03.